This HTML5 document contains 137 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/pubchem-compound/
n30http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/national-drug-code-directory/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/chemspider/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n31http://www.drugs.com/cdi/
n23http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/wikipedia/
n21http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00598/identifier/kegg-compound/
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00598
rdf:type
n3:Drug
n3:description
Blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. [PubChem]
n3:dosage
n24:271B534E-363D-11E5-9242-09173F13E4C5 n24:271B534F-363D-11E5-9242-09173F13E4C5 n24:271B5350-363D-11E5-9242-09173F13E4C5 n24:271B5351-363D-11E5-9242-09173F13E4C5 n24:271B5352-363D-11E5-9242-09173F13E4C5 n24:271B5353-363D-11E5-9242-09173F13E4C5 n24:271B5354-363D-11E5-9242-09173F13E4C5 n24:271B5355-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
6-8 hours
n3:indication
For the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.
n3:manufacturer
n9:271B533E-363D-11E5-9242-09173F13E4C5 n9:271B533F-363D-11E5-9242-09173F13E4C5 n9:271B533C-363D-11E5-9242-09173F13E4C5 n9:271B533D-363D-11E5-9242-09173F13E4C5 n9:271B5340-363D-11E5-9242-09173F13E4C5 n9:271B5341-363D-11E5-9242-09173F13E4C5 n9:271B5336-363D-11E5-9242-09173F13E4C5 n9:271B5337-363D-11E5-9242-09173F13E4C5 n9:271B5335-363D-11E5-9242-09173F13E4C5 n9:271B533A-363D-11E5-9242-09173F13E4C5 n9:271B533B-363D-11E5-9242-09173F13E4C5 n9:271B5338-363D-11E5-9242-09173F13E4C5 n9:271B5339-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00598 n29:DB00598
dcterms:title
Labetalol
adms:identifier
n8:3869 n10:C07063 n11:0172-4364-60 n13:46505511 n14:25758 n15:DB00598 n18:6343 n19:3734 n25:Labetalol n26:PA164743150
n3:mechanismOfAction
Labetalol HCl combines both selective, competitive, alpha-1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. The principal physiologic action of labetalol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. This causes a decrease in systemic arterial blood pressure and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity.
n3:packager
n9:271B531A-363D-11E5-9242-09173F13E4C5 n9:271B531B-363D-11E5-9242-09173F13E4C5 n9:271B5322-363D-11E5-9242-09173F13E4C5 n9:271B5323-363D-11E5-9242-09173F13E4C5 n9:271B5320-363D-11E5-9242-09173F13E4C5 n9:271B5321-363D-11E5-9242-09173F13E4C5 n9:271B531E-363D-11E5-9242-09173F13E4C5 n9:271B531F-363D-11E5-9242-09173F13E4C5 n9:271B531C-363D-11E5-9242-09173F13E4C5 n9:271B531D-363D-11E5-9242-09173F13E4C5 n9:271B5315-363D-11E5-9242-09173F13E4C5 n9:271B5316-363D-11E5-9242-09173F13E4C5 n9:271B5313-363D-11E5-9242-09173F13E4C5 n9:271B5314-363D-11E5-9242-09173F13E4C5 n9:271B5319-363D-11E5-9242-09173F13E4C5 n9:271B5317-363D-11E5-9242-09173F13E4C5 n9:271B5318-363D-11E5-9242-09173F13E4C5 n9:271B532A-363D-11E5-9242-09173F13E4C5 n9:271B532B-363D-11E5-9242-09173F13E4C5 n9:271B5328-363D-11E5-9242-09173F13E4C5 n9:271B5329-363D-11E5-9242-09173F13E4C5 n9:271B5326-363D-11E5-9242-09173F13E4C5 n9:271B5327-363D-11E5-9242-09173F13E4C5 n9:271B5324-363D-11E5-9242-09173F13E4C5 n9:271B5325-363D-11E5-9242-09173F13E4C5 n9:271B5332-363D-11E5-9242-09173F13E4C5 n9:271B5333-363D-11E5-9242-09173F13E4C5 n9:271B5330-363D-11E5-9242-09173F13E4C5 n9:271B5331-363D-11E5-9242-09173F13E4C5 n9:271B532E-363D-11E5-9242-09173F13E4C5 n9:271B532F-363D-11E5-9242-09173F13E4C5 n9:271B532C-363D-11E5-9242-09173F13E4C5 n9:271B532D-363D-11E5-9242-09173F13E4C5 n9:271B5334-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
These metabolites are present in plasma and are excreted in the urine, and via the bile, into the feces.
n3:synonym
3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol Labetolol Labetalolum 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide Labetalol
n3:toxicity
LD<sub>50</sub> = 66 mg/kg (Rat, IV). Side effects or adverse reactions include dizziness when standing up, very low blood pressure, severely slow heartbeat, weakness, diminished sexual function, fatigue
n4:hasAHFSCode
n30:24-24-00
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
50%
n3:salt
n3:synthesisReference
U.S. Patent 4,012,444.
n27:hasConcept
n28:M0012098
foaf:page
n21:nor1301.shtml n23:labet.htm n31:labetalol.html
n3:IUPAC-Name
n6:271B535A-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5360-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B535F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B535C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B535D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B535E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5370-363D-11E5-9242-09173F13E4C5 n6:271B5358-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5356-363D-11E5-9242-09173F13E4C5 n6:271B5372-363D-11E5-9242-09173F13E4C5 n6:271B5359-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5357-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:C07AG01
n3:H-Bond-Acceptor-Count
n6:271B5366-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5367-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5361-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5362-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5364-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5363-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5365-363D-11E5-9242-09173F13E4C5
n3:absorption
Completely absorbed (100%) from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The absolute bioavailability of labetalol is increased when administered with food.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n6:271B5373-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
36894-69-6
n3:category
n3:containedIn
n22:271B5342-363D-11E5-9242-09173F13E4C5 n22:271B5343-363D-11E5-9242-09173F13E4C5 n22:271B534A-363D-11E5-9242-09173F13E4C5 n22:271B534B-363D-11E5-9242-09173F13E4C5 n22:271B5348-363D-11E5-9242-09173F13E4C5 n22:271B5349-363D-11E5-9242-09173F13E4C5 n22:271B5346-363D-11E5-9242-09173F13E4C5 n22:271B5347-363D-11E5-9242-09173F13E4C5 n22:271B5344-363D-11E5-9242-09173F13E4C5 n22:271B5345-363D-11E5-9242-09173F13E4C5 n22:271B534C-363D-11E5-9242-09173F13E4C5 n22:271B534D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B536C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B536E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B536F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5371-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B536B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B536A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B536D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B535B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B5368-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5369-363D-11E5-9242-09173F13E4C5